Company Filing History:
Years Active: 2015-2016
Title: Innovations of Dong-Heon Lee
Introduction
Dong-Heon Lee is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, his work has the potential to impact cancer treatment and research significantly.
Latest Patents
One of Dong-Heon Lee's latest patents is focused on human monoclonal antibodies that neutralize vascular endothelial growth factor receptors. This invention relates specifically to human ScFv molecules that inhibit angiogenesis and can be used in cancer treatment. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies against vascular endothelial growth factor receptors. Furthermore, it shows the capability to neutralize these receptors in humans, mice, and rats, making it a valuable asset in anticancer studies.
Career Highlights
Dong-Heon Lee is currently associated with Pharmabcine Inc., where he continues to innovate in the field of biotechnology. His work is characterized by a commitment to advancing medical science and improving therapeutic options for cancer patients.
Collaborations
He has collaborated with notable colleagues, including Jin-San Yoo and Weon-Sup Lee, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Dong-Heon Lee's contributions to the field of biotechnology, particularly through his patents on monoclonal antibodies, highlight his role as a key inventor in cancer research. His work not only advances scientific understanding but also holds promise for future therapeutic applications.